Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A pilot study of increasing dose intensity of epirubicin and ifosfamide inpatients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor
Autore:
Philip, PA; Rea, D; Mitchell, K; Carmichael, J; Harris, AL; Talbot, DC;
Indirizzi:
Univ Oxford, Imperial Canc Res Fund, Clin Oncol Unit, Oxford, England UnivOxford Oxford England c Res Fund, Clin Oncol Unit, Oxford, England
Titolo Testata:
CLINICAL ONCOLOGY
fascicolo: 2, volume: 11, anno: 1999,
pagine: 84 - 89
SICI:
0936-6555(1999)11:2<84:APSOID>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
INDUCTION CHEMOTHERAPY; CARCINOMA; INTENSIFICATION; DOXORUBICIN; REGIMENS; BREAST;
Keywords:
dose intensity; epirubicin; granulocyte colony-stimulating factor; ifosfamide; small cell lung cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Philip, PA Wayne State Univ, Karmanos Canc Inst, Div Hematol & Oncol, 509 Hudson Bldg,3990 John R St, Detroit, MI 48201 USA Wayne State Univ 509 Hudson Bldg,3990 John R St Detroit MI USA 48201
Citazione:
P.A. Philip et al., "A pilot study of increasing dose intensity of epirubicin and ifosfamide inpatients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor", CL ONCOL-UK, 11(2), 1999, pp. 84-89

Abstract

The aim of this prospective study was to investigate the feasibility of increasing the dose intensity of chemotherapy in patients with small cell lung cancer (SCLC) by using recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF). Seventeen previously untreated patients (11 male, 6 female) were treated with ifosfamide (5.0 g/m(2)) and epirubicin (80 mg/m(2)) in two successive cohorts. Eight patients received chemotherapy every 2 weeks and r-metHuG-CSF 5 mu g/kg given subcutaneously daily for 10 days (cohort A), and nine patients received chemotherapy at 10-day intervals with r-metHuG-CSF 5 mu g/kg subcutaneously given daily for 7 days (cohort B). The relative dose intensity compared with the conventional 3-weekly regimen was 1.5 and 2.1 for cohorts A and B, respectively. Neutropenia-associatedfever complicated two and five treatment courses in cohorts A and B, respectively. There were five episodes of grade 3/4 thrombocytopenia. There wereno treatment delays in cohort A and one cycle was delayed in cohort B. Onepatient from each cohort was withdrawn due to toxicity. Grade 3/4 non-haematological toxicity, other than alopecia, was not observed. This study confirms that it is feasible to increase the relative dose intensity of ifosfamide and epirubicin in patients with SCLC to 2.1 by using r-metHuG-CSF and shortening the interval between treatment cycles.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 12:55:40